Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer.

ABSTRACT: Niraparib (Zejula™) is a PARP inhibitor which is approved for maintenance therapy in adults with advanced ovarian cancer in complete or partial response to platinum-based chemotherapy. In a placebo-controlled phase III trial in patients with newly diagnosed advanced ovarian cancer, niraparib significantly extended progression free survival in two predefined populations, namely a patient population with altered homologous-recombination DNA repair pathways [i.e. homologous-recombination deficiency positive (HRd)] and the overall trial population. A prespecified exploratory subgroup analysis indicated that niraparib was also efficacious in patients who were homologous recombination deficiency negative or homologous recombination proficient (HRp). Niraparib has a manageable tolerability profil

SUBMITTER: Lee A 

PROVIDER: S-EPMC8613118 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature